Consistently high complete and overall response rates in newly-diagnosed multiple myeloma patients shown with Velcade (bortezomib) for injection based therapies.

(From Chemical Business NewsBase - Press Release)

Millennium Pharmaceuticals Inc announced results from studies exploring Velcade alone, or in combination with other commonly used agents, for previously untreated multiple myeloma. Overall response rates as high as 92%, with complete response rates as high as 30% were achieved. These results were presented in independent oral presentations at the 47th Annual Meeting of the American Society of Hematology (ASH) being held from 10-13 Dec 2005, in Atlanta, GA. Overall response rates of 95% have been previously reported with Velcade based therapy in this setting. A Phase I/II trial led by Dr M Victoria Mateos, of the Grupo …